Pharma giant Roche has completed the sale of its solid and liquid formulation facility in Segrate, Italy, to CMO Delpharm, which reached a deal to supply the Swiss pharma giant with product produced at the plant.
The divestment to Delpharm was completed last week, a spokeswoman told FiercePharmaManufacturing. Financial terms were not disclosed.
“Delpharm acquires the site as it is, taking over its people and assets,” Roche spokeswoman Anja von Treskow said in an email. “The agreement between Roche and Delpharm includes a multiyear manufacturing contract, where it is intended that Delpharm will continue to support solid and liquid forms production for Roche in the future.”
The Segrate facility is the second in Italy for Delpharm, which has 12 plants overall.
Late last year, Roche announced it would close or sell four plants, including Segrate, and lay off 1,200 people as part of its plan to transition to new technology for manufacturing small-molecule drugs. It plans to build a late-stage technical development and launch facility in Switzerland for targeted, high-potency drugs.
As part of the agreement with Roche, Delpharm will keep on all the plant’s employees at the Segrate plant.